Navigation Links
Dendritic cell vaccine for relapsed neuroblastoma patient induces complete remission
Date:1/29/2013

One year after his last treatment, a six-year-old boy with recurrent neuroblastoma is in complete remission for his high-risk metastatic cancer. Doctors reported this case study in the January 2013 issue of Pediatrics, the journal of the American Academy of Pediatrics, which was funded in part by a joint grant from the Andrew McDonough B+ Foundation, Pierce Phillips Charity and Solving Kids' Cancer.

Current treatments for high-risk neuroblastoma patients include chemotherapy, radiation therapy, surgery, stem cell transplant, and immunotherapy. Less than half of the children survive in spite of the intensive and toxic standard therapy. Long term survival after a relapse is less than 5%.

Previous clinical trials in adult solid tumors have successfully used cancer-specific targets (NY-ESO-1, MAGE-A1, and MAGE-A3) to kill cancer cells. Now, scientists at the University of Louisville have used these same targets for neuroblastoma by creating a vaccine that causes the body's own immune system to attack the tumor cells. Dendritic cells are immune cells collected from the patient and grown in cultures after they are exposed to specific antigens. The dendritic cells "teach" the patient's T-cells to seek out and kill the cancer cells after they are returned to the patient through a series of injections.

Cancer treatment vaccines differ from other vaccines in that they treat active cancers or help to prevent recurrence. The principal investigator for this study, Kenneth Lucas, M.D., is the division chief of Pediatric Hematology-Oncology and Stem Cell Transplantation at the University of Louisville Department of Pediatrics. The funding provided critical support to further Dr. Lucas' ongoing work to find new treatments for neuroblastoma and other deadly childhood cancers.

In the case study, one year after the patient's last vaccination, the tumors cells that were located in the boy's bone marrow disappeared and he now shows no evidence of disease.

The study includes children with sarcomas as well as neuroblastoma, and will be completed in 2013.

For patients with relapsed neuroblastoma, there are few promising treatment options in clinical trials. More effective and less toxic treatments are desperately needed.

"This research builds on five years of pre-clinical research, which identified three new immunological targets that are specific to this pediatric cancer," said Scott Kennedy, the Executive Director of Solving Kids' Cancer. "The case study highlights the potential therapeutic progress that can be made against neuroblastoma, and brings hope to patients and their families in finding a lasting cure."


'/>"/>

Contact: Jenny Song
jenny@solvingkidscancer.org
Solving Kids' Cancer
Source:Eurekalert

Related medicine news :

1. After 100 years, understanding the electrical role of dendritic spines
2. SIgN scientists discover dendritic cells key to activating human immune responses
3. The long arm of the dendritic cell
4. Whooping Cough Vaccine for Pregnant Women Among New Recommendations
5. NIH-developed candidate dengue vaccine shows promise in early-stage trial
6. Children with egg allergies can safely receive flu vaccine, U-M study says
7. How Cervical Cancer Vaccines Came to Be
8. Vaccines Might Become Another Way to Fight Cancer
9. FDA Approves New Type of Flu Vaccine
10. Childhood Vaccine Schedule Is Safe, Report Says
11. Spot Shortages of Flu Vaccine, Tamiflu Reported, FDA Head Says
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2017)... ... June 23, 2017 , ... Yesterday, U.S. Senate Republicans revealed ... repeal and replace the Affordable Care Act (ACA). Like the bill narrowly passed ... Medicaid, a public health insurance program for low-income children, pregnant women, parents of ...
(Date:6/23/2017)... , ... June 23, 2017 , ... Everybody has their ... while others prefer to read it, and some people don't like it at all. ... Here's what they found: , Erotic literature can give readers a taste of their ...
(Date:6/23/2017)... ... , ... 21 Middle East and South Asia Leaders Selected as Eisenhower Fellows ... and civil society in 11 countries across the Middle East and South Asia to ... exchange of knowledge and ideas with the leading minds in their fields. , ...
(Date:6/23/2017)... ... 23, 2017 , ... Ulster University, Magee Campus in Northern Ireland is hosting ... pm to present to graduate students exciting new and innovative hope research based on ... by The Health Improvement Service of the Western Health & Social Care Trust (WHSCT) ...
(Date:6/23/2017)... ... June 23, 2017 , ... Moore Insurance, an eastern Texas ... to asset protection and financial planning services, is teaming up with the For ... of children with cancer and other chronic diseases. , The For A Day ...
Breaking Medicine News(10 mins):
(Date:6/1/2017)... 2017 Nutriceutical Holdings (NH), parent company of ... and KD Pharma Group have decided to join forces ... Pharma Group. KD Pharma Group will become the largest ... the entire company. "We believe we have ... to growing the NH companies by providing us with ...
(Date:5/30/2017)... , May 30, 2017 Hill-Rom Holdings, Inc. (NYSE: ... Annual Global Healthcare Conference on Tuesday, June 13, 2017, in ... Greisch , Hill-Rom,s president and chief executive officer, is scheduled ... live audio webcast can be accessed at http://ir.hill-rom.com/events.cfm . ... of the live event through September 13, 2017. ...
(Date:5/29/2017)... AVIV, Israel, May 29, 2017  Cellect Biotechnology Ltd. ... innovative technology which enables the functional selection of stem ... results for the first quarter ended March 31 st ... with our accomplishments in the first quarter of 2017," ... first quarter, we announced the treatment of the first ...
Breaking Medicine Technology: